Beam Therapeutics Inc. BEAM
Beam Therapeutics Inc. (Nasdaq: BEAM) is a hematology drug developer. Its lead program, risto-cel (BEAM-101), is in Phase 2 for Sickle cell disease. Its next catalyst on record is risto-cel: BLA submission (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: risto-cel — BLA submission (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| risto-cel | sickle cell disease | cell therapy | Phase 2 |
| BEAM-302 | AATD | gene therapy | Phase 2 |
Recent results and decisions
- Aug 4, 2026started First patient dosed in July 2026 in the global pivotal cohort of the BEAM-302 Phase 1/2 trial in AATD lung disease.
In July, Beam dosed the first patient in the global pivotal cohort of the ongoing Phase 1/2 trial evaluating BEAM-302 in patients with AATD-associated lung disease, with or without liver disease.
Filing - May 7, 2026positive Updated BEAM-302 Phase 1/2 data (announced in March) showed rapid, durable increases in total and functional AAT and decreased Z-AAT, well tolerated up to 75 mg; 60 mg chosen as optimal dose.
Treatment with BEAM-302 led to rapid and durable increases of total and functional AAT, decreases in mutant Z-AAT, and new production of corrected M-AAT, with a well-tolerated safety profile across single doses up to 75 mg.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.